NRX Pharmaceuticals, Inc. — Net Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d1c707a4-f94d-4385-be2e-17b6a41f2a4c/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-28.6M | 2025-01-01 – 2025-12-31 | evidence 0001437749-26-009418 |
| FY 2024 | $-25.1M | 2024-01-01 – 2024-12-31 | evidence 0001437749-25-007743 |
| FY 2023 | $-30.1M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-004396 |
| FY 2022 | $-39.8M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-005292 |
| FY 2021 | $-93.1M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-004899 |
| FY 2020 | $-51.8M | 2020-01-01 – 2020-12-31 | evidence 0001558370-22-004899 |
| FY 2019 | $408.4k | 2019-01-01 – 2019-12-31 | evidence 0001654954-20-003527 |
| FY 2018 | $66.1k | 2018-01-01 – 2018-12-31 | evidence 0001654954-19-002833 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
NRX Pharmaceuticals, Inc. — all facts · Revenue · Operating Income